PCI of rGel-EGF was highly effective against EGFR-expressing squamous cell carcinoma cells (SCC-026 and A-413) and even against cell lines resistant to the EGFR inhibitor cetuximab. The gene discussed is EGFR; the disease is squamous cell carcinoma.